ABSTRACT
AIM: This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM). METHODS: Drug-naive subjects (n = 901) were enrolled into this 28-week, double-blind, parallel-group study if their glycosylated haemoglobin A(1c) (HbA(1c)) was >7.5% but Subject(s)
Adiponectin/metabolism
, Diabetes Mellitus, Type 2/drug therapy
, Glycated Hemoglobin/metabolism
, Hypoglycemic Agents/administration & dosage
, Sulfonylurea Compounds/administration & dosage
, Thiazolidinediones/administration & dosage
, Adolescent
, Adult
, Aged
, Diabetes Mellitus, Type 2/metabolism
, Double-Blind Method
, Female
, Humans
, Hypoglycemia/chemically induced
, Hypoglycemia/drug therapy
, Insulin Resistance
, Lipids
, Male
, Middle Aged
, Practice Guidelines as Topic
, Rosiglitazone
, Treatment Outcome
, Young Adult
